

## **Institutional Biosafety Committee**

### **September 8, 2004 - Minutes**

Present: D. Charney, D. Calfee, F. Erlitz, P Hauck, R. Miller, J. Moline, R, Wieder, L. Egan, S. Strauss, J. Wetmur, K. Sadock

#### **1. Meeting Format**

Discussion centered on insuring an appropriate level of public awareness without compromising the appropriate proprietary interests of investigators.

Passed: Minutes will be posted on the MSSM web site, redacted as necessary for confidentiality regarding proprietary material. [ Also to protect Researcher's Identity]\*\*  
Deliberations will be summarized and rationale for approval in minutes will cite numbers from RAC. [ For research submitted to RAC for prior-approval]\*\*  
Meeting dates will be posted on the web site: <http://www.mssm.edu/biosafety/>  
Notice will appear that those who wish to address the committee should contact the Institutional Biosafety Officer, Mr. Philip Hauck ([Philip.Hauck@mssm.edu](mailto:Philip.Hauck@mssm.edu)) 10 days before the meeting.

#### **2. Charter and Mission Statement**

3. The Charter and Mission Statement of the Mount Sinai School of Medicine Institutional Biosafety Committee were reviewed and approved with the following modifications:

- a. The word “establish” in line 1 will be changed to “maintain.”  
Under section 3, item “i” will be added:  
“Approve standard operating procedures for handling biohazardous materials”
- b. Under section 3, item “j” will be added:  
“Provide training for members of the Committee.”  
“The Chair of the Committee will update the group regularly on relevant issues.”
- c. Under section 5 will be added item a:  
“Investigators must notify the IBC Chair and the Grants and Contracts Office in writing of any adverse event within 24 hours of the event and in an annual report.”
- d. Any research related accident must be reported to the Biosafety Officer  
This directive will be included in the information packet given to Principal Investigators

- e. The Committee will develop training materials, including on-line exercises, for investigators.
- f. More extensive training will be provided for those who must access the BSL-3+ facility.

### 3.. Training for IBC Members

- a. The Institutional Biosafety Officer will provide to the Committee updates on developments in biosafety and will include notices on the IBC web page

### 4. Re-review 23 Active Protocols

		GCO #	Title	BSL
1		01-0189	Viral interferon antagonists virulence	2
2		02-0627	Intrathecal gene transfer for cancer pain	1
3		00-1106	Closed	--
4		00-0529	Closed	--
5		03-0579	Factor IX tolerance in hemophilia gene therapy	1
6		03-0427	Reconstitution of HIV-1 assembly in murine cells	2
7		96-0582	Combination gene therapy for metastatic colon cancer	2
8		02-1135	Cellular protein interactions with viral inhibitors	2
9		79-0163	Porphyria and human heme biosynthesis	2
10		02-0262	Lentiviral mediated gene transfer to kidney	2
11		00-0070	Terminated	--
12		00-0935	Helper-free fully-deleted adenovirus vector system	2
13		00-0074	Integration of AAV2 genome to muscle-specific DNA region	1
14		96-0308	Th1 and Th2 Responses in viral immunity	2
15		02-0349	Closed	--
16		01-0981	Epithelial gene expression in HIV nephropathy	2
17		91-0040	Acid sphingomyelinase & Niemann-Pick disease	1
18		00-0118	E. coli based vectors for gene delivery to cells	1
19		00-0905	Suppression of hepatic gluconeogenesis in IDDM	2
20		----	Interleukin 12 gene therapy for colon cancer	2
21		01-0712	Vector core production facility at MSSM	--
22		02-0520	Oncolytic VSV for hepatocellular carcinoma	(2)
23		02-0513	Genetic reconstitution for phenylketonuria	(1)

5. **Review Significant protocols about to start at BSL 3**

- a. PPG on 1918 influenza to develop complementary DNA molecules to be used as libraries to rebuild certain core subsets of the 1918 influenza virus. Recombinant viruses (which are attenuated) are suitable for work at BSL 2 and will be used to do analysis on inserted 1918 flu genes. Insertion work will be done at the USDA BSL 3 Ag facility. **Current work at Mount Sinai approved at level 2 .**
  
- b. Microbiology will begin a Center of Excellence project on agents of mass destruction. The Newcastle Disease Virus (NDV) is the Hitchner strain obtained from the USDA that is used for vaccinating chickens and poultry. It is attenuated and can be worked with under BSL-2 conditions. **Current work at level approved 2.**

\*\* [ ] = Clarification insertion to provide better understanding of the foregoing sentence or paragraph.